AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

EMINENCE MINERALS LTD

0.052

0.000

Volume:240.43K

Turnover:13.03K

Market Cap:9.98M

PE:-6.33

High:0.055

Open:0.054

Low:0.050

Close:0.052

52wk High:0.120

52wk Low:0.031

Shares:191.90M

Float Shares:82.24M

Volume Ratio:1.26

T/O Rate:0.29%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.008

EPS(LYR):-0.008

ROE:-6.82%

ROA:-4.50%

PB:0.53

PE(LYR):-6.34

Loading ...

Overview Company News Filings

Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug

MT Newswires Live

XRP Presents Strongest Move Since Dropping Below 50 EMA

BRIEF-Eminence Minerals Awards Drilling Contract For 2,000M Rare Earth Drill Program

Eminence Minerals - Awards Drilling Contract for Campo Grande Project in Brazil

THOMSON REUTERS

BRIEF-Eminence Minerals Secures Firm Commitments For A$2.5 Million Placement

Eminence Minerals Ltd-Secures Firm Commitments for $2.5M Placement

THOMSON REUTERS

Eminence Minerals - Placement to Issue 56.22 Mln Shares at a$0.045, Raising a$2.53 Mln in Two Tranches

THOMSON REUTERS

BRIEF-Eminence Minerals Seeks Trading Halt

Eminence Minerals - Trading Halt Request Relates to Material Capital Raising

THOMSON REUTERS

Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease

Actinogen Medical Reaches Common Understanding With European Regulator on Pathway to Marketing Approval for Alzheimers' Disease Program

MT Newswires Live

Suzhou Ribo Seeks Coronary Artery Disease Drug Trial in Europe

MT Newswires Live

AmChamSG Recognizes Inaugural Green Planet Champions

Suzhou Ribo Seeks Venous Thromboembolism Drug Trial in Europe

MT Newswires Live

Emera Q1 Adjusted Earnings, Revenue Rise

MT Newswires Live

Earnings Flash (EMA) Emera Posts Q1 Adjusted EPS CA$1.37, vs. FactSet Est of CA$1.20

MT Newswires Live

Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies

MT Newswires Live

Clinuvel Pharmaceuticals Set for Phase 3 Vitiligo Study After Final Advice From European Medicines Agency

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/EMA.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EMA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"EMA.AU\",,,,,undefined,":{"symbol":"EMA.AU","market":"AU","secType":"STK","nameCN":"EMINENCE MINERALS LTD","latestPrice":0.052,"timestamp":1791522720000,"preClose":0.052,"halted":0,"volume":240429,"delay":0,"changeRate":0,"nameEN":"EMINENCE MINERALS LTD","floatShares":82243410,"shares":191902200,"eps":-0.008213,"marketStatus":"Market Closed","change":0,"latestTime":"10-09 16:12:00 AEDT","open":0.054,"high":0.055,"low":0.05,"amount":13029,"amplitude":0.096154,"askPrice":0.052,"askSize":5014,"bidPrice":0.045,"bidSize":25276,"shortable":3,"etf":0,"ttmEps":-0.008213,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791759600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.052,"openAndCloseTimeList":[[1791500400000,1791522000000]],"volumeRatio":1.2603861849691629,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"EMA.AU","preClose":0.052,"auctionPrice":0.054,"auctionVolume":18178,"auction":3,"marketStatus":"盘后竞价","timestamp":1791522000553}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"EMA.AU\",,,,,undefined,":{"symbol":"EMA.AU","floatShares":82243410,"roa":"-4.50%","roe":"-6.82%","lyrEps":-0.0082,"volumeRatio":1.2603861849691629,"shares":191902200,"dividePrice":0,"high":0.055,"amplitude":0.096154,"preClose":0.052,"low":0.05,"week52Low":0.031,"pbRate":"0.53","psRate":"22.40","week52High":0.12,"institutionHeld":0,"latestPrice":0.052,"committee":0.668934,"eps":-0.008213,"divideRate":0,"volume":240429,"delay":0,"ttmEps":-0.008213,"open":0.054,"prevYearClose":0.066,"prevWeekClose":0.042,"prevMonthClose":0.042,"prevQuarterClose":0.042,"fiveDayClose":0.042,"twentyDayClose":0.043,"sixtyDayClose":0.04},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643510567","title":"Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2643510567","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643510567?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:34","pubTimestamp":1781609689,"startTime":"0","endTime":"0","summary":"Zai Lab  said Tuesday that the European Medicines Agency  has granted orphan drug designation to its experimental therapy, zocilurtatug pelitecan, for the treatment of pulmonary neuroendocrine carcinomas, a type of lung cancer.The company said the designation follows a recommendation from the EMA's Committee for Orphan Medicinal Products, which cited preliminary clinical data suggesting that the therapy may offer a clinically meaningful advantage over currently approved treatments for relapsed or refractory extensive-stage small cell lung cancer, including the potential for durable responses.Zai Lab said the orphan designation provides regulatory incentives that may support the therapy's development, including potential market exclusivity upon approval, reduced regulatory fees, and enhanced regulatory support.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2488822045.USD","BK4588","BK4585","ZLAB","BK4531","BK7129","EMA.AU","BK4139","BK4548","EMA","BK4156","BK4081","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643207889","title":"XRP Presents Strongest Move Since Dropping Below 50 EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2643207889","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643207889?lang=en_us&edition=fundamental","pubTime":"2026-06-15 10:33","pubTimestamp":1781490780,"startTime":"0","endTime":"0","summary":"After weeks of intense selling pressure, XRP is finally beginning to show signs of life.The asset experienced a severe correction that drove it toward the $1.10 region after breaking below the 50-day ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/xrp-presents-strongest-move-since-dropping-below-50-ema","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/xrp-presents-strongest-move-since-dropping-below-50-ema","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["XXRP","BITW","XRP","EMA","XRPK","BK7129","TOXR","XRPZ","XRPT","EMA.AU","UXRP","XRPR","XRPC","BK4081","XRPI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642725538","title":"BRIEF-Eminence Minerals Awards Drilling Contract For 2,000M Rare Earth Drill Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2642725538","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642725538?lang=en_us&edition=fundamental","pubTime":"2026-06-12 09:32","pubTimestamp":1781227931,"startTime":"0","endTime":"0","summary":"BRIEF-Eminence Minerals Awards Drilling Contract For 2,000M Rare Earth Drill ProgramJune 12  - Eminence Minerals Ltd EMA.AX:-AWARDS DRILLING CONTRACT FOR 2,000M RARE EARTH DRILL PROGRAMAWARDS DRILLING CONTRACT FOR CAMPO GRANDE PROJECT IN BRAZILFurther company coverage: EMA.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nTUE5S5VSF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7129","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642237654","title":"Eminence Minerals - Awards Drilling Contract for Campo Grande Project in Brazil","url":"https://stock-news.laohu8.com/highlight/detail?id=2642237654","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642237654?lang=en_us&edition=fundamental","pubTime":"2026-06-12 06:21","pubTimestamp":1781216469,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUE5S5VSF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EMA.AU","BK7129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642471746","title":"BRIEF-Eminence Minerals Secures Firm Commitments For A$2.5 Million Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2642471746","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642471746?lang=en_us&edition=fundamental","pubTime":"2026-06-11 06:45","pubTimestamp":1781131551,"startTime":"0","endTime":"0","summary":"BRIEF-Eminence Minerals Secures Firm Commitments For A$2.5 Million PlacementJune 11  - Eminence Minerals Ltd EMA.AX:SECURES FIRM COMMITMENTS FOR $2.5M PLACEMENTPLACEMENT TO ISSUE 56.22 MILLION SHARES AT A$0.045, RAISING A$2.53 MILLION IN TWO TRANCHESALL FIGURES IN AUDFurther company coverage: EMA.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nTUE3KYY4F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7129","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642910471","title":"Eminence Minerals Ltd-Secures Firm Commitments for $2.5M Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2642910471","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642910471?lang=en_us&edition=fundamental","pubTime":"2026-06-11 06:27","pubTimestamp":1781130463,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nTUE3KYY4F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7129","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642719444","title":"Eminence Minerals - Placement to Issue 56.22 Mln Shares at a$0.045, Raising a$2.53 Mln in Two Tranches","url":"https://stock-news.laohu8.com/highlight/detail?id=2642719444","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642719444?lang=en_us&edition=fundamental","pubTime":"2026-06-11 06:27","pubTimestamp":1781130463,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nTUE3KYY4F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EMA.AU","BK7129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642379264","title":"BRIEF-Eminence Minerals Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2642379264","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642379264?lang=en_us&edition=fundamental","pubTime":"2026-06-09 07:01","pubTimestamp":1780959698,"startTime":"0","endTime":"0","summary":"BRIEF-Eminence Minerals Seeks Trading Halt June 9 (Reuters) - Eminence Minerals Ltd EMA.AX:TRADING HALT REQUEST RELATES TO MATERIAL CAPITAL RAISINGFurther company coverage: EMA.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nFWN42G0Z8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7129","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642379114","title":"Eminence Minerals - Trading Halt Request Relates to Material Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2642379114","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642379114?lang=en_us&edition=fundamental","pubTime":"2026-06-09 07:00","pubTimestamp":1780959653,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nFWN42G0Z8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7129","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638656566","title":"Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2638656566","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638656566?lang=en_us&edition=fundamental","pubTime":"2026-05-28 10:43","pubTimestamp":1779936180,"startTime":"0","endTime":"0","summary":"Coronary artery disease  remains a leading cause of morbidity and mortality globally, driven by atherosclerotic plaque formation and associated thrombotic complications such as myocardial infarction and other ischemic events. Despite the widespread use of standard of care therapies, including antiplatelet and anticoagulant therapies, a substantial residual risk of thrombotic events remains in patients with stable CAD, even when treated with optimized treatment. Current therapies are further limited by an increased risk of bleeding, restricting their intensity and long-term use in many patients. Consequently, there is a significant unmet medical need for novel antithrombotic approaches that can provide effective and sustained protection against thrombosis while maintaining a favorable safety profile, particularly with respect to bleeding risk.\"We are very pleased to advance our anti-thrombotic siRNA programs into the next stage of clinical development in Europe. This milestone reflects ","market":"us","thumbnail":"https://mma.prnewswire.com/media/2804420/logo_Ribolia_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2804420/logo_Ribolia_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ribo-announces-phase-2-clinical-trial-submission-to-ema-further-advancing-sirna-therapeutics-in-thromboembolic-disease-302783857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA.AU","EMA","BK4007","BK4081","CAD.AU","BK7129","BK7095","BK7504","BK4139","CTA","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638653254","title":"Actinogen Medical Reaches Common Understanding With European Regulator on Pathway to Marketing Approval for Alzheimers' Disease Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2638653254","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638653254?lang=en_us&edition=fundamental","pubTime":"2026-05-28 09:53","pubTimestamp":1779933233,"startTime":"0","endTime":"0","summary":"Actinogen Medical  reached a common understanding of the pathway to marketing approval for its Alzheimer's disease program in its scheduled scientific advice meeting with the European Medicines Agency , according to a Thursday Australian bourse filing.The understanding includes the specification of regulatory starting materials for the commercial manufacturing of Xanamem  drug substance, design considerations for an additional pivotal clinical trial, as well as the limited number of ancillary clinical pharmacology trials and nonclinical studies required.The understandings also include ensuring the proposed makeup of the planned safety database is consistent with EMA and US Food and Drug Administration  guidelines.The firm said the understandings align closely with the guidance received at an earlier meeting with the US FDA's Neurology-I division.Actinogen Medical's shares rose nearly 3% in recent trading on Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA.AU","EPV","BK7067","BK4081","BK7129","BK7508","EMA","ACW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638653364","title":"Suzhou Ribo Seeks Coronary Artery Disease Drug Trial in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2638653364","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638653364?lang=en_us&edition=fundamental","pubTime":"2026-05-28 09:33","pubTimestamp":1779932024,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for RBD1119 at the European Medicines Agency (EMA), according to a Thursday filing with the Hong Kong bourse.The trial aims to study the drug for the treatment of coronary artery disease.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","EMA","EMA.AU","BK1161","BK7129","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636853691","title":"AmChamSG Recognizes Inaugural Green Planet Champions","url":"https://stock-news.laohu8.com/highlight/detail?id=2636853691","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636853691?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:21","pubTimestamp":1779189660,"startTime":"0","endTime":"0","summary":"2026 AmChamSG Green Planet Energy Forum celebrates leadership and commitment to advancing a more sustainable and resilient energy future.SINGAPORE, May 19, 2026 /PRNewswire/ -- The American Chamber of Commerce in Singapore  recognized the inaugural Green Planet Champions at the 2026 AmChamSG Green Planet Energy Forum on Friday, May 15, 2026, with Guest of Honor Dr. Tan See Leng, Minister for Manpower and Minister-in-charge of Energy and Science & Technology, Ministry of Trade and Industry.During the fireside chat, Minister Tan discussed Singapore's journey in energy transition and how Singapore has managed energy security amid geopolitical developments and global uncertainties.About AmCham Singapore Established in 1973, the American Chamber of Commerce in Singapore  is the largest and the most active international business association in Singapore and Southeast Asia, with over 600 American and other global companies with significant U.S. business interests. AmChamSG is an independent, ","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2983129/image1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2983129/image1.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/amchamsg-recognizes-inaugural-green-planet-champions-302776090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","EMA.AU","BK7129","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634780283","title":"Suzhou Ribo Seeks Venous Thromboembolism Drug Trial in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2634780283","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634780283?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:20","pubTimestamp":1778498424,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for Vortosiran at the European Medicines Agency (EMA), according to a Monday Hong Kong bourse filing.The trial aims to study the drug for the prevention of venous thromboembolism.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA","06938","BK4081","BK7129","EMA.AU","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432748","title":"Emera Q1 Adjusted Earnings, Revenue Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432748","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633432748?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:31","pubTimestamp":1778236298,"startTime":"0","endTime":"0","summary":"Emera  reported Q1 adjusted earnings Friday of 1.37 Canadian dollars  per share, up from CA$1.28 a year earlier.Analysts polled by FactSet expected CA$1.20.Revenue for the quarter ended March 31 was CA$2.81 billion, up from CA$2.68 billion a year earlier.Three analysts polled by FactSet expected CA$2.42 billion.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA.AU","EMA","BK4081","BK7129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633543476","title":"Earnings Flash (EMA) Emera Posts Q1 Adjusted EPS CA$1.37, vs. FactSet Est of CA$1.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2633543476","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633543476?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:10","pubTimestamp":1778235035,"startTime":"0","endTime":"0","summary":"Earnings Flash (EMA) Emera Posts Q1 Adjusted EPS CA$1.37, vs. FactSet Est of CA$1.20","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CA","EMA","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630333203","title":"Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2630333203","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630333203?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:14","pubTimestamp":1777248895,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  is unlikely to seek regulatory approval for Scenesse in vitiligo until the Phase 3 CUV105 and CUV107 clinical trials are completed, according to a Friday Jefferies note.The company said on Friday that the European Medicines Agency  has proposed evaluating the company's Scenesse drug for the treatment of systemic vitiligo based on a \"totality of evidence\" regulatory approach.Jefferies said that the EMA's decision is a positive for the company because of the high unmet medical need for Vitiligo treatment.The investment firm has pushed back its revenue expectations from Scenesse in vitiligo, which is now expected to begin in the second half of fiscal 2029 rather than fiscal 2028.Jefferies kept a buy rating on Clinuvel and cut its price target to AU$39.20 from AU$40.50.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA.AU","CUV.AU","BK7067","BK7508","BK7129","BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629862958","title":"Clinuvel Pharmaceuticals Set for Phase 3 Vitiligo Study After Final Advice From European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2629862958","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629862958?lang=en_us&edition=fundamental","pubTime":"2026-04-24 08:10","pubTimestamp":1776989406,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) said the European Medicines Agency (EMA) has proposed evaluating the company's Scenesse drug for the treatment of systemic vitiligo based on a \"totality of evidence\"","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","EMA","BK7067","BK4081","CUV.AU","BK7508","BK7129","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":38,"code":"91000000","status":"200"}]}}